CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
+0.45%Aug 11, 2026, 13:16 UTC
C4 Therapeutics, Inc. reported a Q2 loss of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.23 and improving from a loss of $0.37 per share a year ago.
Source: